R&D News | pharmaphorum

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Amgen scientists working in the lab, one woman and one man

Amgen scores with new thyroid eye disease formulation

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

Ambrosia's sweet $100m round, and other biofinancings

Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.

News

Immunovant's thyroid eye disease drug flunks pivotal trials

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

News

AZ claims another win for Imfinzi in frontline liver cancer

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

News

Alzheimer's biotech Korsana to go public via reverse merger

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Amgen scores with new thyroid eye disease formulation

Ambrosia's sweet $100m round, and other biofinancings

Immunovant's thyroid eye disease drug flunks pivotal trials

AZ claims another win for Imfinzi in frontline liver cancer

Alzheimer's biotech Korsana to go public via reverse merger

Ultragenyx to slash costs after Angelman trial failure

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks